Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Has files: YesSubject: search.filters.subject.COVID

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    A Comparative Olfactory MRI, DTI and fMRI Study of COVID-19 Related Anosmia and Post Viral Olfactory Dysfunction
    (ELSEVIER SCIENCE INC, 2022-01-01) Yildirim, Duzgun; Kandemirli, Sedat Giray; Sanli, Deniz Esin Tekcan; Akinci, Ozlem; Altundag, Aytug
    Rationale and Objective: To evaluate how COVID-19 anosmia imaging findings resembled and differed from postinfectious olfactory Material and Methods: A total of 31 patients presenting with persistent COVID-19 related OD and 97 patients with post-infectious OD were included. Olfactory bulb MRI, DTI and olfactory fMRI findings in both groups were retrospectively assessed. Results: All COVID-19 related OD cases were anosmic, 18.6\% of post-infectious OD patients were hyposmic and remaining 81.4\% were anosmic. Mean interval between onset of OD and imaging was 1.5 months for COVID-19 related OD and 6 months for post-infectious OD. Olfactory bulb volumes were significantly higher in COVID-19 related OD than post-infectious OD. Deformed bulb morphology and increased olfactory bulb signal intensity was seen in 58.1\% and 51.6\% with COVID-19 related OD
  • Thumbnail Image
    Item
    Pharmacokinetic characterization of favipiravir in patients with COVID-19
    (WILEY, 2022-01-01) Gulhan, Rezzan; Eryuksel, Emel; Oglu, Medine Gulcebi Idriz; Culpan, Yekta; Toplu, Aylin; Kocakaya, Derya; Tigen, Elif; Sengel, Buket Erturk; Sili, Uluhan; Yildizeli, Sehnaz Olgun; Balcan, Mehmet Baran; Elci, Abdullah; Bulut, Cenk; Karaalp, Atila; Yananli, Hasan Raci; Guner, Abdullah Emre; Hatipoglu, Mustafa; Karakurt, Sait; Korten, Volkan; Ratnaraj, Neville; Patsalos, Philip; Ay, Pinar; Onat, Filiz
    This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID-19 with a positive RT-PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in-hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID-19. The median favipiravir trough concentration (C0-trough) on Day 2 was 21.26 (interquartile range {[}IQR], 8.37-30.78) mu g/mL, whereas it decreased significantly to 1.61 (IQR, 0.00-6.41) mu g/mL on Day 4, the area under the concentration-time curve decreased by 68.5\%. Day 2 C0-trough of female patients was higher than male patients. Our findings indicate that favipiravir concentrations show significant variability during the treatment of COVID-19 and therapeutic drug monitoring may be necessary to maintain targeted concentrations.